CAR T‐cell therapy shows impressive outcomes for patients with refractory multiple myeloma

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, CAR T‐cell therapy shows impressive outcomes for patients with refractory multiple myeloma. In addition, an analysis of real‐world evidence on the use of comprehensive genomic profiling in patients with metastatic cancer showed its effectiveness in matching targeted therapy, and low‐dose olanzapine is effective and safe for preventing chemotherapy‐induced nausea and vomiting.